a public good project by the
Synthesis
Company
of California

© 2026

Mary Campbell | doi.page

0 works0 citations0 h-index

Mary Campbell

Harvard University(US)Massachusetts General Hospital(US)Providence Center(US)Providence Health & Services(US)

Publications by Year

Research Areas

Cancer Genomics and Diagnostics, Genomics and Rare Diseases, Cancer Immunotherapy and Biomarkers, Cancer Cells and Metastasis, HER2/EGFR in Cancer Research

Most-Cited Works

→ A Community‐Based Outbreak of Severe Respiratory Illness Caused by Human Adenovirus Serotype 14(2009)158 cited
→ Multiplex immunofluorescence to measure dynamic changes in tumor-infiltrating lymphocytes and PD-L1 in early-stage breast cancer(2021)68 cited
→ Multicenter evaluation of the Bayer VERSANT™ HIV-1 RNA 3.0 assay: analytical and clinical performance(2002)60 cited
→ Determination of varicella-zoster virus (VZV) immune status with the VIDAS VZV immunoglobulin G automated immunoassay and the VZVScan latex agglutination assay(1996)8 cited
→ Sex-dependent increases in oxytocin levels in response to intravenous kisspeptin in humans(2025)7 cited
→ A phase Ib trial of pembrolizumab plus paclitaxel or flat-dose capecitabine in 1st/2nd line metastatic triple-negative breast cancer(2023)6 cited

→ Geno4ME Study: implementation of whole genome sequencing for population screening in a large healthcare system(2025)

5 cited

→ Recurrence of head and neck squamous cell cancer following resection may be predicted by assessment of immune infiltrates within the tumor (TUM10P.1056)(2015)2 cited

→ Design and validation of a clinical whole genome sequencing-based assay for patient screening in a large healthcare system(2025)

→ A phase Ib trial evaluating the safety, efficacy, and immunologic effects of pembrolizumab plus paclitaxel or flat-dose capecitabine in 1st/2nd line metastatic triple-negative breast cancer(2022)